Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (441-450 of 962) with videos related to

Pageof 97
Sort By:
European Heart Journal|April 15, 2014
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trialDaniel Lindholm, Christoph Varenhorst, Christopher P Cannon, et al.
European Heart Journal. Imaging Methods and Practice|April 13, 2026
New CT-based dural ectasia criteria using machine learning to diagnose Marfan and Loeys-Dietz syndromesClaire Bouleti, Raphael Thuillier, Yoann Moeuf, et al.
BMJ (Clinical Research Ed.)|June 21, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trialStefan K James, Matthew T Roe, Christopher P Cannon, et al.
European Heart Journal|April 8, 2011
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyJosé R Banegas, Esther López-García, Jean Dallongeville, et al.
Journal of the American College of Cardiology|March 25, 2014
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesElaine M Hylek, Claes Held, John H Alexander, et al.
The American Journal of Medicine|November 28, 2013
NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic diseasePayal Kohli, Ph Gabriel Steg, Christopher P Cannon, et al.
Pharmacoepidemiology and Drug Safety|March 28, 2026
Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial InfarctionThomas Cars, Stefan Gustafsson, Queenie Chan, et al.
JACC. Cardiovascular Interventions|February 26, 2011
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary interventionFreek W A Verheugt, Steven R Steinhubl, Martial Hamon, et al.
European Heart Journal|August 2, 2011
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesRobert F Storey, Richard C Becker, Robert A Harrington, et al.
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Pageof 97

Showing results (441-450 of 962) with videos related to

Sort By:
Pageof 97
European Heart Journal|April 15, 2014
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trialDaniel Lindholm, Christoph Varenhorst, Christopher P Cannon, et al.
European Heart Journal. Imaging Methods and Practice|April 13, 2026
New CT-based dural ectasia criteria using machine learning to diagnose Marfan and Loeys-Dietz syndromesClaire Bouleti, Raphael Thuillier, Yoann Moeuf, et al.
BMJ (Clinical Research Ed.)|June 21, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trialStefan K James, Matthew T Roe, Christopher P Cannon, et al.
European Heart Journal|April 8, 2011
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyJosé R Banegas, Esther López-García, Jean Dallongeville, et al.
Journal of the American College of Cardiology|March 25, 2014
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesElaine M Hylek, Claes Held, John H Alexander, et al.
The American Journal of Medicine|November 28, 2013
NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic diseasePayal Kohli, Ph Gabriel Steg, Christopher P Cannon, et al.
Pharmacoepidemiology and Drug Safety|March 28, 2026
Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial InfarctionThomas Cars, Stefan Gustafsson, Queenie Chan, et al.
JACC. Cardiovascular Interventions|February 26, 2011
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary interventionFreek W A Verheugt, Steven R Steinhubl, Martial Hamon, et al.
European Heart Journal|August 2, 2011
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesRobert F Storey, Richard C Becker, Robert A Harrington, et al.
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Pageof 97